
an Economist Intelligence Unit business healthcare
Case studies: Renal replacement services; Ultra orphan drugs
Commissioning briefs can be thought of as "due diligence” for commissioners who are deciding whether to invest in or disinvest from particular services, drugs, diagnostics and devices. They address all the issues – cover all the bases – required for commissioning in a rational, transparent and evidence-based way. Commissioning briefs are independent yet robust, allowing commissioners and clinicians to more quickly decide a course of action, set policy and make commissioning and other allocation decisions.
Commissioning briefs contain:
Commissioning briefs are used for:
“The work done on PAVR with Bazian brought together commissioners, clinicians and academics to ensure that the commissioning of this new, innovative procedure will be based on sound evidence. This will benefit future NHS patients, and has demonstrated that we can introduce new technologies through a robust research-led approach. It also provided a model for introducing innovations to the NHS in the future through a collaborative process based on World Class Commissioning.”
Kate Caston, Director of East Midlands Specialised Commissioning